[Federal Register: March 4, 2005 (Volume 70, Number 42)]
[Notices]
[Page 10678-10679]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr04mr05-107]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated November 1, 2004, and published in the Federal
Register on November 10, 2004, (69 FR 65229), Guilford Pharmaceuticals,
Inc., 6611 Tributary Street, Baltimore, Maryland 21224, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk
[[Page 10679]]
manufacturer of Cocaine (9041), a basic class of controlled substance
listed in Schedule II.
The company plans to manufacture a cocaine derivative to be used as
an intermediate for the production of Dopascan Injection. Cocaine
derivatives are a Schedule II controlled substance in the cocaine basic
class.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Guilford Pharmaceuticals, Inc. to manufacture the listed basic classes
of controlled substances is consistent with the public interest at this
time. DEA has investigated Guilford Pharmaceuticals, Inc. to ensure
that the company's registration is consistent with the public interest.
The investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with State and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
Dated: February 22, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-4198 Filed 3-3-05; 8:45 am]
BILLING CODE 4410-09-P